ADA-EASD Position Statement: Management of Hyperglycemia in T2DM
{"Image DocumentName": "ADA-EASD Position Statement: Management of Hyperglycemia in T2DM", "Image ImageDescription": "4. OTHER CONSIDERATIONS. Comorbidities. Coronary Disease. Heart Failure. Renal disease. Liver dysfunction. Hypoglycemia. Metformin: CVD benefit (UKPDS) Avoid hypoglycemia. ? SUs & ischemic preconditioning. ? Pioglitazone & \uf0af CVD events. ? Effects of incretin-based therapies. Diabetes Care 2012;35:1364\u20131379. Diabetologia 2012;55:1577\u20131596.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}